Surgical robotics pioneer Stereotaxis (NYSE American: STXS) announced a definitive agreement to acquire French robotic catheter company Robocath for up to $45 million, the company disclosed in April 2026 and reaffirmed during its first-quarter 2026 earnings release on May 12, 2026. The deal would make Stereotaxis one of the few platforms able to serve the full spectrum of endovascular procedures with both magnetic navigation and mechanical robotic catheter control.
Deal terms and timeline
Stereotaxis will pay $20 million upfront with up to $25 million in additional milestone-based payments tied to regulatory and commercial achievements. The transaction is subject to customary closing conditions and is expected to close in mid-2026. Robocath is expected to generate about $2 million in annual revenue in the first year after closing, with the deal targeted to break even by year three.
How the two robotic platforms fit together
Stereotaxis uses computer-controlled magnetic fields to remotely steer the distal tip of interventional devices through the heart's chambers and the vasculature — a technology used in electrophysiology and increasingly in structural heart and neurointerventional procedures. Robocath's flagship R-One+ system, by contrast, manipulates the proximal end of interventional devices at the bedside. Combined, the two platforms can deliver multi-device, fully robotic control across coronary and neurovascular workflows, with a planned next-generation system designed to simultaneously manipulate up to five interventional devices.
Robocath's installed base in Europe
Robocath's R-One+ is the only commercially available robotic platform for percutaneous coronary intervention (PCI) in Europe, with 15 systems installed globally. The company has recently performed first-in-human procedures with a next-generation platform in France. The acquisition gives Stereotaxis an immediate European footprint and a clinical pipeline already cleared for PCI cases.
Why endovascular robotics is heating up
The deal lands as surgical robotics consolidates across multiple categories. Intuitive Surgical rolled out telepresence and extended-use force feedback for the da Vinci 5, while peer Asensus, Medtronic Hugo and CMR Surgical's Versius Plus continue to expand FDA-cleared indications. Investors are pricing in a structural shift to robotic-assisted procedures across cardiology and neurology, where vendor concentration has long lagged orthopedics and laparoscopy.
What Stereotaxis is buying beyond the catheters
Beyond the R-One+ platform, the acquisition brings clinical workflows, regulatory infrastructure and a multi-device manipulation roadmap. Stereotaxis said the combined company will be uniquely positioned to deliver "next-generation fully-integrated robotic solutions" for electrophysiology, interventional cardiology and neurointerventions. The companies plan to operate as a unified entity post-close, with Robocath's commercial and engineering teams folding into Stereotaxis's broader endovascular strategy. Related to the broader medtech robotics push, the Boston Robotics Summit recently showcased BCI and surgical robotics breakthroughs.
Why this matters for patients
For patients, the combination is positioned to deliver more precise, reproducible robotic procedures in cardiology and neurology — fields where complications are heavily operator-dependent and where remote-capable robotic platforms could help mitigate the impact of regional specialist shortages.
Reporting based on coverage from MedTech Dive, The Robot Report and Stereotaxis's investor disclosures.